Zimmer Biomet Coughs Up at Least $132 Million for MEDTECH
Zimmer Biomet (NYSE:ZBH) said today that it agreed to pay at least $132 million to acquire French robot-assisted surgery firm Medtech (EPA:ROSA).
Warsaw, Ind.-based Zimmer Biomet has already paid €50.00 per share ($55.39) for more than 1.4 million ROSA shares, which is about 58.77% of the Montpellier, France-based company’s stock, to founder & CEO Bertin Nahum, Newfund and other owners. Zimmer Biomet also put up €50.03 ($55.43) for per Medtech’s convertible bonds and €17.17 ($19.02) for its warrants, both of which were owned by Ally Bridge Group.
Warsaw, Ind.-based Zimmer Biomet has already paid €50.00 per share ($55.39) for more than 1.4 million ROSA shares, which is about 58.77% of the Montpellier, France-based company’s stock, to founder & CEO Bertin Nahum, Newfund and other owners. Zimmer Biomet also put up €50.03 ($55.43) for per Medtech’s convertible bonds and €17.17 ($19.02) for its warrants, both of which were owned by Ally Bridge Group.